Metastatic Breast Cancer

Metastatic Breast Cancer

Stay informed on the latest news and clinical advances.

A 61-Year-Old Woman With Painful Constipation A 61-year-old woman with a history of stage III breast cancer 7 years prior presents to a primary care clinic with painful constipation. Do you know how best to help her?
Medscape, October 12, 2017

Alert FDA Approves Abemaciclib (Verzenio) for Advanced HR+ Breast Cancer The new drug is similar to two other cyclin-dependent kinase (CDK) 4/6 inhibitors, but it also has some distinguishing qualities.
FDA Approvals, September 28, 2017
ESMO Abemaciclib: First-Line CDK4/6 Inhibitor for Breast Cancer Abemaciclib, the third CDK4/6 inhibitor, in combination with endocrine therapy shows significant benefit for the first-line treatment of HR+ HER2- advanced breast cancer.
Medscape Medical News, September 11, 2017
Fibromatosis-like Spindle Cell Carcinoma of the Breast This case describes the clinical and imaging findings of a rare triple negative, fibromatosis-like metaplastic spindle cell breast carcinoma.
Applied Radiology, August 7, 2017
Abemaciclib: Another CDK 4/6 Inhibitor for Breast Cancer Abemaciclib is heading toward approval and could soon become the third of a new class of drugs for use in breast cancer, joining palbociclib and ribociclib.
Medscape Medical News, July 25, 2017

Potential ASCO Practice-Changers in HER2+ Breast Cancer Oncologists will debate the APHINITY trial data for years to come, says Dr Kevin Kalinsky.
Medscape Oncology, July 7, 2017
New CDK4/6i Data Move Metastatic Breast Cancer Field Forward At ASCO 2017, the MONARCH-3, PALOMA-1, AND TREnd trials shed light on the efficacy of new CDK4/6 inhibitors for metastatic breast cancer.
Medscape Oncology, June 27, 2017

A 61-Year-Old Woman With Painful Constipation A 61-year-old woman with a history of stage III breast cancer 7 years prior presents to a primary care clinic with painful constipation. Do you know how best to help her?
Medscape, October 12, 2017

Fast Five Quiz: Systemic Treatment for Metastatic Breast Cancer Although treatments for metastatic breast cancer are improving, no cure has been found once distant metastases develop. How much do you know about systemic treatment for metastatic breast cancer?
Medscape, April 13, 2017

Renowned leaders offer insight on emerging research affecting the treatment and quality of life of patients with metastatic breast cancer.

Fatima Cardoso, MD Director, Breast Cancer Unit, Champalimaud Cancer Center, Lisbon, Portugal
Coordinator, Breast Cancer Program, European School of Oncology, Milan, Italy
Co-chair, Advanced Breast Cancer International Consensus Guidelines Conference
Ann H. Partridge, MD, MPH Associate Professor, Department of Medicine, Harvard Medical School
Founder and Director, Program for Young Women with Breast Cancer
Director, Adult Survivorship Program, Dana-Farber Cancer Institute, Boston, Massachusetts

Hope S. Rugo, MD Professor of Medicine
Director, Breast Oncology and Clinical Trials Education
Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco

	What new treatment approaches to metastatic breast cancer do you consider the most promising?
		CDK inhibitors, such as palbociclib, in ER-positive/HER2-negative disease
		Fulvestrant as first-line treatment
		mTOR inhibitors, such as everolimus, as first-line treatment
		Dual anti-HER2 therapy in HER2-positive disease
		PARP inhibitors in patients with functional BRCA1/BRCA2 deficiency

	In your experience, to what extent have financial considerations affected the choice of treatment plan for patients with metastatic breast cancer?
		Never
		A small minority of cases
		About half of cases
		The majority of cases
		Cost is always a consideration